Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.
Rapid Initiation of SGLT2 Inhibitors Improves Cost-Effectiveness of Therapy, with Ankeet Bhatt, MD, MBA
Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data
In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.
The APAC Recap: Lifestyle Medicine at CAPP Live 2024 with Laura Ross, PA-C
Laura Ross, PA-C, shares insights from the inaugural CAPP meeting on how lifestyle medicine and targeted therapies are transforming cardiovascular care.
Diabetes Dialogue: Latest Updates on Semaglutide
In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C
Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
In this latest episode of Lungcast, multiple points of view are highlighted regarding Aspirin-Exacerbated Respiratory Disease (AERD).
Ahmad Masri, MD, MS: Reaching New Milestones in Cardiovascular Gene Therapy Development
Masri discussed the new phase 3 trial of Intellia’s NTLA-2001 or nex-z.
Naim Alkhouri, MD: First Real-World Data for Resmetirom Use in Clinical Practice
Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.
Ellen Sher, MD: Cross-Specialty Collaboration Can Improve Atopic Dermatitis Management
IgAN Progression
Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).
Overview of IgAN and Its Common Symptoms
Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.
Novel Gas-Sensing Capsule May Provide New Tool for Assessing Motility Disorders
Braden Kuo, MD, explains how the gas-sensing capsule compares to the FDA-cleared, but now discontinued, SmartPill wireless motility capsule.
Stool Diary App Aids Vibrating Capsule Compliance, Efficacy for Chronic Constipation
Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.
Mazen Noureddin, MD: Differences in Resmetirom Efficacy Based on Body Weight, BMI
Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.
Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH
Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
This interview at the Fall Clinical Dermatology Conference features a discussion with Stein Gold regarding the open-label extension of the phase 3 ADORING trial regarding tapinarof.
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitinib for Uveitis
At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD
At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.
